Ligand Pharmaceuticals (LGND) Research & Development (2010 - 2026)

Ligand Pharmaceuticals has disclosed Research & Development across 17 years of filings, most recently posting $2.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $2.1 million, down 95.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.2 million (down 49.27% YoY), and the FY2025 annual result was $81.2 million, up 278.91% from the prior year.
• Research & Development came in at $2.1 million for Q1 2026 at Ligand Pharmaceuticals, down from $3.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $50.1 million in Q1 2025 to a low of $2.1 million in Q1 2026.
• The 5-year median for Research & Development is $6.6 million (2025), against an average of $9.7 million.
• Across the five-year window, Research & Development surged 738.8% in 2025 and slumped 95.71% in 2026, its largest moves.
• Ligand Pharmaceuticals' Research & Development stood at $9.2 million in 2022, then tumbled by 40.33% to $5.5 million in 2023, then retreated by 19.37% to $4.4 million in 2024, then slipped by 20.66% to $3.5 million in 2025, then tumbled by 38.82% to $2.1 million in 2026.
• The last three Research & Development figures came in at $2.1 million (Q1 2026), $3.5 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.